The cuts to the AIDS Drug Assistance Program (ADAP), which will reduce the income eligibility for aid and remove a key medication from coverage, are slated to take effect on March 1.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data from its phase 1 study of long-acting formulations of VH184, ...

At 48 weeks, 1% of participants in both groups had an HIV-1 RNA level of 50 copies per milliliter or higher, meeting the prespecified noninferiority margin of 4%. Rates of viral suppression below 50 ...

Gilead Sciences posted results from a Phase 3 trial showing its HIV treatment was effective. The trial of bictegravir 75 mg/lenacapavir 50 mg was also well-tolerated and demonstrated the potential to ...

A new study led by researchers from the CUNY Institute for Implementation Science in Population Health (ISPH) finds that the ...

A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), could ...

A single-pill treatment to suppress HIV proved as effective as existing therapies of up to 11 tablets daily, the latest advance in a scientific “golden age” for treating the virus even as rich ...